Back

Adherence and discontinuation of sglt2-inhibitors and glp1-r agonists in patients with type 2 diabetes with and without cardiovascular disease

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Anti-diabetic pharmacotherapy in clinical practice Antidiabetic Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speakers

Photo
Doctor Mariam Elmegaard

Gentofte University Hospital, Copenhagen (Denmark)

Photo
Doctor Alexander Christian Falkentoft

Zealand University Hospital, Roskilde (Denmark)

5 More presentations in this session

Presentation thumbnail
The DPP4 inhibitor linagliptin exacerbated heart failure due to energy deficiency via downregulation of glucose absorption and utilization in mice.
Doctor A. Shiraki (Saga, JP)
Abstract Slides
Presentation thumbnail
Empagliflozin rescues primary murine cardiac fibroblasts, but not cardiomyocytes, from hypoxia-reoxygenation injury through STAT3-mediated cascades.
Mrs P. Nikolaou (Athens, GR)
Abstract Slides
Presentation thumbnail
Anti-inflammatory potential of SGLT2 inhibitors: a systematic review and meta-analysis of preclinical studies in rodents
Doctor M. Sagris (Athens, GR)
Abstract Slides
Presentation thumbnail
Four-months treatment with dapagliflozin improves endothelial glycocalyx and cardiovascular function in patients with type 1 diabetes mellitus.
Doctor I. Ikonomidis (Athens, GR)
Abstract Slides
Presentation thumbnail
Absolute treatment effects for the primary outcome and all-cause mortality in the cardiovascular outcome trials in type 2 diabetes: a meta-analysis of individual patient data
Mr G. Wolff (Ibbenbüren, DE)
Abstract Slides

Access the full session

Session thumbnail
Anti-diabetic pharmacotherapy in clinical practice

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Case 1 - a middle-aged male with T2DM: polypharmacy in a primary prevention setting
thumbnail
Congress Presentation
Hypertension and glucose
thumbnail
Congress Presentation
Cardiovascular risk reduction: should we target pre-diabetes?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources